YTHDF2 and hepatocellular carcinoma: Hou et al. reported that reduced expression of YTHDF2 in HCC tumor tissues was accompanied by increases in m6A methylation and mRNA expression, and was associated with unfavorable survival outcomes and poor clinical classification (28).